WALTHAM, Mass.--(BUSINESS WIRE)--March 14, 2006--Dynogen Pharmaceuticals, Inc. announced today that it has initiated a Phase II trial of DDP225 in patients with chronic functional vomiting (CFV) and the first patients have been dosed. This Phase II trial is a randomized, double-blinded, placebo controlled study that is assessing multiple symptom-based endpoints. The trial is being conducted at multiple U.S. sites. CFV is the second clinical indication for DDP225, an orally-active compound that targets two key pathways that control the gastrointestinal (GI) system. Dynogen initiated a Phase II trial for DDP225 in patients with diarrhea-predominant irritable bowel syndrome (IBS-d) in October 2005.
